Evidence map›Paper›PMID 40266661›Full record

ArticleMicrobial genomics2025

Genomic characterization of group B

Veronica Kovacec, Sabrina Di Gregorio, Mario Pajon, Uzma Basit Khan, Tomas Poklepovich, Josefina Campos, Chiara Crestani, Stephen D Bentley, Dorota Jamrozy, Marta Mollerach and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbial genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Veronica KovacecUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Bacteriología y Virología Molecular, Buenos Aires C1113, Argentina.
Sabrina Di GregorioUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Bacteriología y Virología Molecular, Buenos Aires C1113, Argentina.
Mario PajonUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Bacteriología y Virología Molecular, Buenos Aires C1113, Argentina.
Uzma Basit KhanParasites and Microbes Programme, Wellcome Sanger Institute, Cambridgeshire CB10 1SA, UK.
Tomas PoklepovichUnidad Operativa Centro Nacional de Genómica y Bioinformática, ANLIS Dr. Carlos G. Malbrán, Buenos Aires C1282AFF, Argentina.
Josefina CamposUnidad Operativa Centro Nacional de Genómica y Bioinformática, ANLIS Dr. Carlos G. Malbrán, Buenos Aires C1282AFF, Argentina.
Chiara CrestaniGlobal Health Department, Institut Pasteur, Paris 75015, France.
Stephen D BentleyParasites and Microbes Programme, Wellcome Sanger Institute, Cambridgeshire CB10 1SA, UK.
Dorota JamrozyParasites and Microbes Programme, Wellcome Sanger Institute, Cambridgeshire CB10 1SA, UK.
Marta MollerachUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Bacteriología y Virología Molecular, Buenos Aires C1113, Argentina.
Laura BonofiglioUniversidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Instituto de Bacteriología y Virología Molecular, Buenos Aires C1113, Argentina.

Funding

Gates Foundation INV-010426Wellcome Trust
6 · The paper itself

Abstract

Group B

Indexed as

Drug Resistance, BacterialProphagesStreptococcal InfectionsStreptococcus agalactiaeVirulence FactorsAnti-Bacterial AgentsArgentinaGenome, BacterialGenomicsHumansPhylogenyWhole Genome SequencingAnti-Bacterial AgentsVirulence FactorsArgentinaepidemiologygroup B Streptococcus (GBS)prophageStreptococcus agalactiae

Identifiers

PMID40266661
PMCPMC12046356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.